GSC
UNCY icon

Ground Swell Capital’s Unicycive Therapeutics UNCY Stock Holding History

Ground Swell Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,912
Closed -$26.4K – 218
2024
Q1 		$26.4K Buy
+1,912
New +$23.2K 0.02% 55
2023
Q3 		– Sell
-2,000
Closed -$25.6K – 114
2023
Q2 		$25.6K Buy
+2,000
New +$31.3K 0.06% 37

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ground Swell Capital's UNCY Position: Q2 2024 in Review

Ground Swell Capital sold out of Unicycive Therapeutics (UNCY) in Q2 2024, closing a stake of 1,912 shares — an estimated $26.4K sold.

Ground Swell Capital first reported a position in UNCY in Q2 2023 and held it in 2 quarters. The position peaked at $26.4K in Q1 2024. 23 funds tracked by Wall St. Rank hold UNCY as of Q2 2024.

  • Ground Swell Capital reported no remaining Unicycive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ground Swell Capital sold 1,912 Unicycive Therapeutics shares in Q2 2024, an estimated $26.4K.
  • Ground Swell Capital first reported a position in Unicycive Therapeutics in Q2 2023 and held it in 2 quarters.
  • Ground Swell Capital's Unicycive Therapeutics position peaked at $26.4K in Q1 2024.
  • 23 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2024.

Based on Ground Swell Capital's 13F filing for Q2 2024, filed 7 Aug 2024.